Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Granules India receives 1 observation from USFDA for Chantilly facility
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Globally, BRUKINSA is approved in more than 70 countries
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
The initiative was announced at World Hypertension Congress, Chennai
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Subscribe To Our Newsletter & Stay Updated
